Enovis raises 2025 adjusted EPS guidance to $3.10–$3.25 while sharpening portfolio focus

Earnings Call Insights: Enovis Corporation (ENOV) Q3 2025

MANAGEMENT VIEW

* CEO Damien McDonald highlighted the company's "solid third quarter results reflect strong performance broadly across the portfolio as we increasingly focus on commercial execution, operational excellence, and capital allocation." He emphasized revenue growth of 9% on a reported basis and 7% organically, with Recon growing 9% and Prevention and Recovery (P&R) up 4% organically. McDonald pointed to the augmented reverse glenoid system (ARG) gaining traction and noted, "We’re still very early in the launch cycle, and there are additional products in the pipeline to support a multiyear cadence of innovation in extremities."
* McDonald detailed international growth of 12%, attributing success to the Lima integration and cross-selling synergies. He reported, "We showcased the next-generation Arvis at ASC in August last month. Surgeon response to Arvis Ultra was outstanding. It's lighter, faster, and adds capabilities like soft tissue balancing for knees and advanced shoulder applications."
* The divestiture of Dr. Comfort was completed in early October. McDonald stated, "This was an important transaction in support of our purposefully shaping our business."
* CFO Phillip Berry said, "We are pleased to report third quarter sales of $549 million, up 9% versus the prior year on a reported basis, including a 190 basis point benefit from foreign currency and 7% organic growth." He added, "Adjusted gross margins improved 140 basis points in the quarter...Adjusted EBITDA margin was 17.3%, down 60 basis points year-over-year, reflecting planned R&D investments, phasing of expenses and tariffs."
* Berry explained a non-cash goodwill impairment of $548 million, attributing it to "a sustained decline in our share price and market capitalization," and clarified, "This impairment does not have any impact on Enovis' liquidity, cash flows, debt covenants, nor does it have any impact on future operations."

OUTLOOK

* Berry announced, "We are updating our full year 2025 outlook. Due to our positive Q3 performance and the divestiture of Dr. Comfort, we are adjusting revenue guidance by $5 million to $2.24 billion to $2.27 billion with no change to our organic growth guidance."
* Berry also raised profit and earnings guidance: "We now expect adjusted EBITDA in the range of $395 million to $405 million. This is a $3 million increase to the range...We are also raising our adjusted EPS guidance by $0.05 to $3.10 to $3.25."
* The company continues to expect positive cash flow for the year, prioritizing debt reduction and lower leverage levels as 2025 concludes.

FINANCIAL RESULTS

* Enovis reported third quarter sales of $549 million, with Recon business up 9% organically and P&R up 4% organically. Year-to-date organic growth stood at 7%.
* Adjusted gross margins increased 140 basis points in the quarter, with adjusted EBITDA margin at 17.3%. Adjusted EPS for the quarter was $0.75, up 3% versus the prior year. Year-to-date adjusted EPS increased 27%.
* Berry reported, "Interest expense was $9 million for the quarter, down from $11 million last year."
* A non-cash goodwill impairment of $548 million was recorded but management stated it has no impact on liquidity or operations.
* The divestiture of Dr. Comfort is expected to reduce Q4 revenue outlook by $15 million.

Q&A

* Vikramjeet Chopra, Wells Fargo: Asked about market slowdowns and 2026 growth. McDonald responded, "Q4 procedure volume seems healthy and stable...right now, we're seeing healthy and stable volumes."
* Chopra followed up on 2026 growth expectations. Berry said, "We still see that as a potential for this business, but we're not guiding on 2026 right now."
* Young Li, Jefferies: Asked about portfolio transformation and further divestitures. McDonald stated, "We're very focused on three things. The commercial execution...operational excellence...and this financial discipline. Everything is on the table, but being very focused on those three things is important for us in the near term."
* Li inquired about Arvis Ultra launch pace. McDonald described strong conference feedback and explained the company is working on "offering lots of flexibility in terms of the financial model for customers to purchase lease or commit to implants."
* Vijay Kumar, Evercore: Asked about U.S. Recon and Arvis impact. McDonald clarified, "No, we haven't seen any impact on implant sales because of the delay." Berry added, "We still believe that U.S. Hip and Knee is a big growth driver for us."
* Kumar probed on Q4 margin guidance. Berry explained, "A 4-plus percent headwind to growth in the quarter...we've paid $10 million year-to-date on tariffs...a modest impact due to the divestiture as well."
* Danielle Antalffy, UBS: Asked about price vs. volume for new launches. McDonald noted, "All of the new product launches, we anticipate will help us mitigate what are market headwinds in price."
* Dane Reinhardt, Baird: Asked about price increases and free cash flow conversion. Berry responded, "We have introduced some increases there to offset some of the impact...We see line of sight to 70% to 80% free cash flow conversion against adjusted net income."

SENTIMENT ANALYSIS

* Analysts focused on risks from tariffs, divestitures, and pricing pressures, with a neutral to slightly positive tone. There was interest in growth momentum and cash flow discipline, while analysts probed on new launches and market headwinds.
* Management maintained a confident and optimistic tone in prepared remarks, frequently using phrases like "we are pleased," "we're very focused," and "we believe our execution...has demonstrated a strong track record." In Q&A, management remained measured and occasionally hedged, as Berry stated, "It's a combination of those things" when discussing margin guidance, and McDonald noted, "Everything is on the table, but being very focused...is important for us."
* Compared to the previous quarter, management continued to project confidence, while analysts maintained their focus on execution and risk mitigation.

QUARTER-OVER-QUARTER COMPARISON

* Adjusted EPS guidance was raised by $0.05 this quarter, following a $0.10 increase the prior quarter. Revenue guidance was adjusted by $5 million this quarter after a $25 million increase last quarter.
* Management’s focus shifted from initial CEO transition and strategic review in Q2 to operational discipline, commercial execution, and portfolio management in Q3.
* Analysts continued to probe on margins, product launches, and cash flow, but pressed more this quarter on the impact of tariffs, divestitures, and Q4 growth headwinds.
* Confidence in new product launches and international growth remained strong, while the company highlighted the benefits of the Dr. Comfort divestiture.
* Management tone was consistent with the previous quarter—optimistic and focused, but with more emphasis on financial discipline and portfolio shaping.

RISKS AND CONCERNS

* Berry highlighted the fluid tariff environment, stating, "The tariff situation remains very fluid. We paid $4 million of tariffs in Q3...we continue to execute against our mitigation action plans."
* The divestiture of Dr. Comfort is expected to reduce Q4 revenue outlook by $15 million, though management plans to absorb the modest margin and cash flow impact.
* A non-cash technical impairment of goodwill was recorded due to share price and market cap declines, but management assured it does not affect liquidity or operations.
* Analysts questioned future pricing power, Q4 growth headwinds, and the impact of tariff and divestiture on margins.

FINAL TAKEAWAY

Enovis delivered strong third quarter growth and raised its adjusted EPS guidance for 2025, signaling confidence in the company’s product innovation and operational execution. The strategic divestiture of Dr. Comfort is sharpening the focus on higher-growth, higher-margin opportunities, while management remains committed to disciplined capital allocation and sustaining free cash flow momentum as the company exits 2025.

Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/enov/earnings/transcripts]

MORE ON ENOVIS CORPORATION

* Enovis Corporation (ENOV) Q3 2025 Earnings Call Transcript [https://seekingalpha.com/article/4839895-enovis-corporation-enov-q3-2025-earnings-call-transcript]
* Enovis: Healthy Recon Trends Vs. Market Apathy [https://seekingalpha.com/article/4817080-enovis-stock-healthy-recon-trends-vs-market-apathy]
* Enovis Corporation beats top-line and bottom-line estimates; updates FY25 outlook [https://seekingalpha.com/news/4517061-enovis-corporation-beats-top-line-and-bottom-line-estimates-updates-fy25-outlook]
* Enovis Corporation Q3 2025 Earnings Preview [https://seekingalpha.com/news/4516065-enovis-corporation-q3-2025-earnings-preview]
* Seeking Alpha’s Quant Rating on Enovis Corporation [https://seekingalpha.com/symbol/ENOV/ratings/quant-ratings]